Egetis Therapeutics AB (publ) Stock Price

OM:EGTX Community·SEK 3.7b Market Cap

3 Narratives written by author
0 Comments on narratives written by author
10 Fair Values set on narratives written by author

Author Program NEW Create Narrative

EGTX Share Price Performance

SEK 8.06

3.05 (60.88%)

SEK 15.33

Fair Value

SEK 8.06

3.05 (60.88%)

47.4% undervalued

SEK 15.33

Fair Value

SEK 8.06

SEK 15.33

SEK 23.00

SEK 11.00

Fri, 7 Aug 26

Fair ValueSEK 15.33

Share Pricen/a

EGTX Community Narratives

AnalystConsensusTarget's

Fair Value

Fair Value SEK 15.33 47.4% undervalued

Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook

AnalystHighTarget's

Fair Value

Fair Value SEK 23 65.0% undervalued

Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside

AnalystLowTarget's

Fair Value

Fair Value SEK 11 26.7% undervalued

Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects

Egetis Therapeutics

47.4% undervalued

Rare Disease Approvals And Rising Diagnostic Awareness Will Transform This Biotech’s Long-Term Outlook

AnalystConsensusTarget

Updated 7 Aug

Read Narrative

Egetis Therapeutics

26.7% undervalued

Single Indication Reliance And Rising Payer Pressures Will Constrain Future Prospects

AnalystLowTarget

Updated 24 Jul

Read Narrative

Egetis Therapeutics

65.0% undervalued

Bullish View Sees Regulatory Momentum And Global Access Infrastructure Driving Long Term Upside

AnalystHighTarget

Updated 26 Jun

Read Narrative

Trending Discussion

No trending discussion available.

Snowflake Analysis

High growth potential with adequate balance sheet.

1 Risk

2 Rewards

View Full Analysis

Egetis Therapeutics AB (publ) Key Details

Last Reported Earnings

Jun 30, 2026

Next Reporting Earnings

Nov 06, 2026

: -0.87
: 16.67%
: -614.24%
: 13.4%

View Full Analysis

About EGTX

Founded: 2006
Employees: 56
CEO: Nicklas Westerholm
WebsiteView website: www.egetis.com

Egetis Therapeutics AB (publ), a pharmaceutical company, engages in the development and commercialization of orphan drugs in Sweden and internationally. It develops Aladote, which is in Phase IIb/III clinical trial for the treatment of paracetamol/acetaminophen overdosing and for the prevention of acute liver failure in paracetamol poisoning; and Emcitate, which is in Phase IIb clinical trial for the treatment of monocarboxylate transporter 8 deficiency. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is headquartered in Stockholm, Sweden.